Search clinical trials for: Dapagliflozin, Farxiga

Total 1065 results

Ann & Robert H Lurie Children's Hospital of Chicago
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease (SGLT2I-IN-KIDS)

Chronic Kidney Diseases | Pediatric Kidney Disease

United States
Hannover Medical School
Boehringer Ingelheim

Not yet recruiting

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) (EMPA-PKD)

Autosomal Dominant Polycystic Kidney
McGill University Health Centre/Research Institute...
Heart and Stroke Foundation of Canada

Recruiting

Canagliflozin in Advanced Renal Disease With MRI Endpoints (CARe-MRI)

ESRD, CKD Stage 4, CKD Stage 5

Canada
Chulalongkorn University

Not yet recruiting

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 (TREAT-CRS)

Empagliflozin in Cardiorenal Syndrome Type 1

Thailand
University Health Network, Toronto

Not yet recruiting

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis (CANARY)

End Stage Kidney Disease | Kidney Dysfunction | Peritoneal Dialysis Complication | Sodium-glucose Co-transporter-2 Inhibitors | Residual Kidney Function

Canada
Chinese University of Hong Kong

Recruiting

Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction (EMPA)

Acute Heart Failure

Hong Kong
Chulalongkorn University

Recruiting

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Empagliflozin in Post AKI Stage 2-3

Thailand
Boehringer Ingelheim

Recruiting

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

Heart Failure

Korea, Republic of
Jacob Moller
Rigshospitalet, Denmark; University Hospital Bispebjerg and Frederiksberg; Hillerod... and other collaborators

Recruiting

The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

Heart Failure | Obesity

Denmark
Assiut University

Completed

Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients (Fatty liver)

Fatty Liver Disease

Egypt
Mutah University

Completed

Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions

Pharmacokinetic Parameters

Jordan
Morten Schou

Completed

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction (Empire HF)

Heart Failure With Reduced Ejection Fraction

Denmark
Medical University of Vienna

Completed

Empagliflozin in Post-Transplantation Diabetes Mellitus (EMPTRA-DM)

Posttransplant Diabetes Mellitus

Austria
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers

Healthy

Belgium
University Hospital, Basel, Switzerland
Boehringer Ingelheim

Recruiting

Empagliflozin for the Treatment of Postprandial Hypoglycemia (EmpHy)

Postprandial Hypoglycemia

Switzerland
University of Sao Paulo General Hospital

Recruiting

iSGLT2 in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump (POST-CABGDM)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury | Coronary Artery Bypass Surgery

Brazil
Royal Perth Hospital

Recruiting

Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans (EMPA-SNS)

Obesity | Type 2 Diabetes Mellitus | Metabolic Syndrome

Australia
Dong Wha Pharmaceutical Co. Ltd.

Completed

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.

Healthy Subjects

Korea, Republic of
National Cheng-Kung University Hospital

Completed

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

Fatty Liver Disease

Taiwan
Samuel Lunenfeld Research Institute, Mount Sinai...
McGill University Health Centre/Research Institute of the McGill University...

Completed

Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting (CLASS17)

Type1 Diabetes Mellitus

Canada
Medical University of Vienna
Attoquant Diagnostics

Completed

EMPRA (EMPagliflozin and RAs in Kidney Disease) (EMPRA)

Diabetes Mellitus, Type 2 | Diabetic Kidney Disease | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3

Austria
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

Healthy

United States
Foundation for Atlanta Veterans Education and Research...
Janssen Scientific Affairs, LLC

Active, not recruiting

Canagliflozin-Mealtime Insulin Rescue

Diabetes Mellitus, Type 2

United States
University Hospital Tuebingen

Completed

Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes

Body Weight | PreDiabetes

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, United Kingdom, Canada, Sweden, Ireland, Argentina, Brazil, Lebanon, Malaysia, Mexico, Italy
Hvidovre University Hospital

Unknown

Glucose Absorption and Gut Hormone Secretion After Gastric Bypass

Overweight

Denmark
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Janssen Research & Development, LLC

Completed

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Ain Shams University

Not yet recruiting

Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.

Nephrotic Syndrome
University of Mississippi Medical Center
Eli Lilly and Company

Recruiting

Empagliflozin in ESKD - A Feasibility Study

Heart Failure | Kidney Failure, Chronic

United States
Children's Hospital of Fudan University

Withdrawn

Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease

Chronic Kidney Diseases | Proteinuria

China
University of Pisa

Unknown

Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy (PURITY)

Glucose Metabolism Disorders | Renal Function Disorder

Italy
Alexandria University

Completed

Empagliflozin as a Novel Therapy in Refractory Ascites

Ascites Hepatic

Egypt
Shengjing Hospital

Completed

CANA/Met in Non-diabetic Women With PCOS

Polycystic Ovary Syndrome

China
Petra Pharma

Unknown

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Lung Cancer | Endometrial Cancer | Colo-rectal Cancer
International Bio service

Not yet recruiting

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Fayoum University
Cairo University

Not yet recruiting

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
Humanis Saglık Anonim Sirketi

Completed

Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

Type2 Diabetes Mellitus

India
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers

Healthy
Pharma Nueva

Not yet recruiting

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Healthy Vollunteer
Kasr El Aini Hospital

Completed

Empagliflozin in Patients With Glomerulonephritis

Proteinuria | Glomerulonephritis

Egypt
University Health Network, Toronto

Recruiting

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial (NATRIURETIC)

Type 2 Diabetes Mellitus

Canada
University of Sao Paulo General Hospital

Recruiting

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI) (SAFE-PCI)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury

Brazil
Janssen Research & Development, LLC

Completed

A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure (CHIEF-HF)

Heart Failure

United States
Yonsei University

Unknown

Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver

Type2 Diabetes | NAFLD - Nonalcoholic Fatty Liver Disease

Korea, Republic of
Université de Sherbrooke
Janssen Inc.

Withdrawn

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF) (Canacardia)

Heart Failure | Type2 Diabetes
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

Type 2 Diabetes Mellitus With Complication
Getz Pharma

Recruiting

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Diabetes Mellitus, Type 2 | NAFLD | NASH - Nonalcoholic Steatohepatitis

Pakistan

3

Subscribe